Evrópusambandið - íslenska - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - Ónæmisbælandi lyf - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret ætti að gefa í ásamt colchicine, ef viðeigandi. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zentiva k.s.* - tenofovirum disoproxil súkkínat - filmuhúðuð tafla - 245 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

evolan pharma ab - sumatriptanum súkkínat - filmuhúðuð tafla - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - sumatriptanum súkkínat - filmuhúðuð tafla - 100 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - sumatriptanum súkkínat - filmuhúðuð tafla - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - sumatriptanum súkkínat - stungulyf, lausn - 12 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

recordati ireland limited* - metoprololum súkkínat; felodipinum inn - forðatafla - 10 mg + 100 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

recordati ireland limited* - metoprololum súkkínat; felodipinum inn - forðatafla - 5 mg + 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - solifenacinum súkkínat - filmuhúðuð tafla - 5 mg